> 首页 > 产品 > 一抗 > 其他 > Anti-IL-13 & IL-4 Reference Antibody (Romilkimab)

Anti-IL-13 & IL-4 Reference Antibody (Romilkimab)

Anti-IL-13 & IL-4 Reference Antibody (romilkimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-IL-13 & IL-4 Reference Antibody (romilkimab) is 97.45%, determined by SEC-HPLC.
Romilkimab bound to IL-4 protein, and then rebounded to secondary antibodies(Anti-Human-κ+λ-HRP) , and read OD450. As shown in fig, Romilkimab bound to Human IL-4-Fc, and the EC50 was 0.040 nM.
Romilkimab bound to IL-3 protein, and then rebounded to secondary antibodies(Anti-6*his-HRP ) , and read OD450. As shown in fig, Romilkimab bound to Human IL-3-His, and the EC50 was 0.088 nM.
The detected molecular weight of Anti-IL-13 & IL-4 Reference Antibody (Romilkimab) is 197.87 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P35225 & P05112
Reactivity	Human
Clonality	Bispecific
Isotype	DVD-Ig

Additional Information
Target/Specificity	IL-13,IL-4
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.